Previous 10 | Next 10 |
2023-11-08 11:01:04 ET Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2023 Earnings Conference Call November 8, 2023, 08:00 AM ET Company Participants Carrie Siragusa - VP of Marketing Lonnel Coats - CEO Tom Garner - Chief Commercial Officer Craig Granowitz - Chief ...
2023-11-08 07:08:47 ET More on Lexicon Pharmaceuticals Looking Back In On Lexicon Pharmaceuticals Lexicon Pharmaceuticals Underway With Inpefa, But A Lot Of Hard Work Lexicon Rolls Out Inpefa For Heart Failure Amid Robust Competition Lexicon to present data o...
Commercial launch of INPEFA ® (sotagliflozin) as a differentiated, new treatment option for heart failure patients shows meaningful progress in Q3 with increasing demand across the cardiology community Significant formulary inclusions effective in Q4 opening...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Lexicon Pharmaceuticals Inc. (LXRX) is expected to report $-0.22 for Q3 2023
2023-11-07 11:49:17 ET Lexicon Pharmaceuticals ( NASDAQ: LXRX ) is scheduled to announce Q3 earnings results on Wednesday, November 8th, before market open. The consensus EPS Estimate is -$0.22 and the consensus Revenue Estimate is $2.06MOver the last 3 months, EPS estimat...
2023-11-07 10:58:25 ET Major earnings expected before the bell on Wednesday include: Biogen ( BIIB ) 3D Systems ( DDD ) Roblox ( RBLX ) Teva Pharmaceutical Industries ( TEVA ) Warner Bros. Discovery ( WBD ) For further details see: Notable...
THE WOODLANDS, Texas, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its third quarter 2023 financial results on Wednesday, November 8 th , 2023 before the markets open. Management will conduct a conference call and live webcast at 8:00 a.m...
Cost-effectiveness data and analyses of financial impact among patients hospitalized for heart failure and treated with INPEFA included as important data selected for presentation INPEFA ® (sotagliflozin) recently approved by FDA for treatment of heart failure...
As previously reported, Express Scripts has also determined that it will list INPEFA as a preferred product on Medicare national formularies starting today, November 1, 2023 INPEFA recently approved by FDA for treatment of heart failure THE WOODLANDS, Texas, Nov. 01, 2023 (G...
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00...
Launch Preparations Actively Underway; Launch Planned for Early 2025 Lexicon Seeks Approval for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease THE WOODLANDS, Texas, July 16, 20...
New analysis of the pivotal Phase 3 SOLOIST-WHF trial provides additional evidence of positive economic impact on hospitals participating in various alternative payment models (APM) Findings consistent with two peer-reviewed studies published in June 2024 THE WOODLANDS, Texa...